Business
DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce that it has obtained all required regulatory and ethics approvals to proceed with the clinical study of TeaRx™ Red Eye previously announced in a press release dated December 2, 2025.As previously disclosed, the Company initiated a collaboration with AlyaTec, a.
About this update from Diagnostear Technologies, Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce that it has obtained all required regulatory and ethics approvals to proceed with the clinical study of TeaRx™ Red Eye previously announced in a press release dated December 2, 2025.","length":441,"tagName":"p"},{"type":"text","content":"As previously disclosed, the Company initiated a collaboration with AlyaTec, a leading Contract Research Organization (CRO) specializing in allergy and environmental diseases, to conduct a clinical study designed to advance the analytical validation and FDA submission pathway of the TeaRx™ Red Eye diagnostic platform.","length":319,"tagName":"p"},{"type":"text","content":"The Company has now received:","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Approval from ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé), the French National Agency for Medicines and Health Products Safety.","length":158,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":158,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"A favourable opinion from the French Ethics Committee (Comité de Protection des Personnes Sud Méditerranée III), which reviewed the study protocol and issued a positive decision following its plenary session.","length":208,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":208,"olType":false},{"type":"text","content":"These approvals enable the clinical study to formally proceed.","length":62,"tagName":"p"},{"type":"text","content":"In addition, AlyaTec has notified the Company that operational readiness has been achieved and that patient recruitment and sampling has commenced.","length":147,"tagName":"p"},{"type":"text","content":"This study is designed to evaluate tear samples collected from documented allergy patients before and after controlled ocular allergy provocation, with the goal of finalizing the analytical validation of total tear IgE as a key biomarker for Allergic Conjunctivitis and further strengthening the scientific and regulatory pathway of TeaRx™ Red Eye, as previously described. The significance o...